Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
The reality gap: testing AI from compliance to enforcement
Companies and regulators often operate with distinct immediate objectives, e.g. profit maximisation versus consumer protection). Yet, as artificial intelligence (AI) increasingly permeates the economy, both sides face a shared challenge: navigating the opacity of complex algorithms. For companies, the primary imperative is risk management. A newly deployed algorithm that inadvertently… Read More
Consumer Duty board reports: what is required for the 2026 editions?
The UK Financial Conduct Authority’s (FCA) Consumer Duty has now been in force for over two years. For many firms, the deadline for the next iteration of their annual Consumer Duty board reports will fall later in 2026. The financial services landscape has changed significantly in the last… Read More